BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

Suppose a cancer patient has been told that he would be free of cancer cells and return to his normal life; that would be the ...

The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple ...

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Researchers sought to determine whether liso-cel could be safely administered as an outpatient therapy in relapsed/refractory LBCL.

T-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...